Haemonetics beats Q4 estimates, stock surges on guidance By Investing.com

Haemonetics beat fiscal Q4 expectations with adjusted EPS of $1.29 vs. $1.27 consensus and revenue of $346.4 million vs. $337.0 million expected, with revenue up 4.8% year over year. The company also issued fiscal 2027 guidance for 4% to 7% reported revenue growth, 3% to 6% organic growth, and 50 to 100 bps of adjusted operating margin expansion, while free cash flow conversion is expected near 80%. Shares surged 17.7% after the release, helped by the earnings beat and outlook, and the company repurchased $100 million of stock in the quarter.

Analysis

The market is likely underestimating the quality of this beat because it is not just a top-line inflection; it also shows the company can absorb tariff and mix pressure while still expanding cash generation. That matters for valuation because cash flow durability typically rerates med-tech names faster than reported EPS, especially when buybacks are meaningful relative to market cap. The 80% FCF conversion target is the key tell: if they actually sustain that through FY27, incremental buybacks can become a larger driver of per-share growth than operating leverage alone.

The more interesting second-order effect is competitive positioning within procedure-dependent med-tech categories. Stronger Plasma and Blood Management performance suggests this franchise is not merely benefiting from a post-pandemic rebound, but from pricing/volume resilience that could pressure smaller peers with less scale and weaker service networks. If guidance proves conservative, the stock can keep working over the next 1-2 quarters as investors extrapolate mid-single-digit organic growth into a cleaner margin story; if it disappoints, the downside is likely to come from margin skepticism rather than demand collapse.

The contrarian risk is that the stock’s jump may have already discounted most of the good news, leaving limited room unless the company shows sustained margin expansion after tariffs. A 50-100 bp margin improvement guide is solid, but not enough to protect the shares if consensus starts to question whether growth is being front-loaded or aided by mix normalization. The next catalyst is less about the reported quarter and more about whether management can deliver sequential improvement in Interventional Technologies and keep repurchase cadence aggressive without leverage creep.

Key Decisions for Investors

• Stay long HAE on a 1-3 month horizon, but prefer buying pullbacks rather than chasing after the gap; risk/reward is strongest if the post-earnings move retraces 5-8% and the market starts to price FY27 guidance as conservative.
• Use HAE as a relative-value long versus lower-quality med-tech peers with weaker free-cash-flow conversion; the pair works best if investors rotate toward balance-sheet repair and buyback-supported earnings per share over the next 1-2 quarters.
• Consider selling out-of-the-money upside calls against an existing HAE position for the next earnings cycle; implied move likely compresses after this print, and the stock may need a second proof point on margins to rerate materially higher.
• If operating margin trends fail to improve by the next quarter, reduce exposure quickly: the stock’s main downside is multiple compression from any hint that tariff pressure or mix headwinds are structurally capping profitability.